Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine on Pulmonary Function After Thoracoscopic Lung Resection
NCT07309393Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in residual neuromuscular block (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Change in Forced Expiratory Volume in 1 Second at 1 hour. Started Dec 2025; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
residual neuromuscular block
Beyond the preview
Go deeper on NCT07309393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309393.